Deep learning detection of acute and sub-acute lesion activity from single-timepoint conventional brain MRI in multiple sclerosis.

Journal: Medical image analysis
Published Date:

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease characterized by demyelinating lesions in the central nervous system. Cross-sectional measurements of acute inflammatory lesion activity are typically obtained by detecting the presence of gadolinium enhancement in lesions, which typically lasts 3-6 weeks. We formulate the novel and clinically relevant task of quantification of recent acute lesion activity from the past 24 weeks (6 months) using single-timepoint conventional brain magnetic resonance imaging (MRI). We develop and compare several deep learning (DL) methods for estimating this brain-level acuteness score and show that a 2D-UNet can accurately predict acute disease activity at the patient-level while outperforming transformers and ensemble approaches. In the context of identifying subjects with acute (less than 6 months-old) lesion activity, our 2D-UNet achieves an area under the receiver-operating curve in the range 80-84% on independent relapsing-remitting MS cohorts. When used in conjunction with measurements of gadolinium-enhancing lesion activity, our model significantly improves the prognostication of future acute lesion activity (over the next 6 months). This model could thus be leveraged for population recruitment in clinical trials to identify a higher number of patients with acute inflammatory activity than current standard approaches (e.g., gadolinium positivity) with a predictable precision/recall trade-off.

Authors

  • Quentin Spinat
    TheraPanacea, Paris, France.
  • Benoit Audelan
    TheraPanacea, Paris, France.
  • Xiaotong Jiang
    College of Mechanical and Electrical Engineering, Nanjing University of Aeronautics and Astronautics, Mailbox 357, 29 Yudao Street, Qinhuai District, Nanjing 210016, PR China. Electronic address: jxt_nuaa@sina.com.
  • Bastien Caba
    Biogen, Cambridge, MA, USA; Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
  • Alexis Benichoux
    TheraPanacea, Paris, France. Electronic address: q.spinat@therapanacea.eu.
  • Despoina Ioannidou
    TheraPanacea, Paris, France.
  • Olivier Teboul
    TheraPanacea, Paris, France.
  • Nikos Komodakis
    TheraPanacea, Paris, France; University of Crete, Greece; IACM-FORTH, Greece; Archimedes/Athena RC, Greece.
  • Willem Huijbers
    Biogen Digital Health, Biogen, Cambridge, Massachusetts.
  • Refaat Gabr
    Biogen, Cambridge, MA, USA.
  • Arie Gafson
    Biogen, Cambridge, MA, USA.
  • Colm Elliott
    NeuroRx Research, Montreal, QC, Canada.
  • Douglas Arnold
    NeuroRx Research, Montreal, QC, Canada.
  • Nikos Paragios
    TheraPanacea, Paris, France.
  • Shibeshih Belachew
    Biogen Digital Health, Biogen, Cambridge, Massachusetts.

Keywords

No keywords available for this article.